MedTrace Logo

Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals

NCT05788185 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-10-16

No results posted yet for this study

Summary

Phase 1b, randomized, open-label, study to evaluate the safety, tolerability, and immunogenicity of RVM-V001 only, RVM-V002 only, or RVM V001 + RVM V002 (Co administered as Separate Injections) in healthy adults. The study will be conducted at one site in Singapore.

Conditions

Interventions

BIOLOGICAL

RVM-V001 30 µg

For BNT162b2 subjects

BIOLOGICAL

RVM-V002 30 µg

For BNT162b2 subjects

BIOLOGICAL

RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration

For BNT162b2 subjects

BIOLOGICAL

RVM-V001 30 µg

For BBIBP-CorV or CoronaVac subjects

BIOLOGICAL

RVM-V002 30 µg

For BBIBP-CorV or CoronaVac subjects

BIOLOGICAL

RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration

For BBIBP-CorV or CoronaVac subjects

Sponsors & Collaborators

  • RVAC Medicines (US), Inc.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-22
Primary Completion
2023-09-21
Completion
2023-09-21

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05788185 on ClinicalTrials.gov